Page 2,669«..1020..2,6682,6692,6702,671..2,6802,690..»

Research and Markets: Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market – Global Industry Size …

Posted: August 22, 2012 at 5:11 pm

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/khwrrx/circulating_tumor) has announced the addition of the "Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018" report to their offering.

The rising prevalence of diseases like cancer and the reimbursement support by regulatory bodies in developed countries like United States and Europe are the major factors driving the growth of the CTCs and CSCs market. Though the currently used detection method lacks sensitivity or specificity to track all CTCs particularly the ones that have lost characteristic epithelial features, there is still good scope for pharmaceutical companies in the CTCs and CSCs field. The various sub-types of cancer may have their own classes and it creates an opportunity in the future.

Increase in cancer mortality rate in the past few years and an increase in number of cancer patients offers an opportunity for pharmaceutical companies to enter this sector. Every one person out of eight has the potential of getting affected by cancer and it is estimated that 12 to 37 lives can be saved daily with the help of CTCs and CSCs.

The major geographic markets for CTCs and CSCs are the U.S. and Europe. The U.S. accounted for more than 50% of the worldwide CTCs and CSC market in 2011.

This research is specially designed to estimate and analyze the demand and performance of CTCs and CSC products in a global scenario. The report covers all the major segments of the global CTC and CSC market and provides in-depth analysis, historical data and statistically refined forecast for the segments covered. The study presents a comprehensive assessment of the stakeholder strategies and winning imperatives for them by segmenting the global CTC and CSC market.

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Market Overview

Visit link:
Research and Markets: Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size ...

Posted in Stem Cells | Comments Off on Research and Markets: Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market – Global Industry Size …

Doctors to study newborn stem cells as treatment for autism

Posted: August 22, 2012 at 5:11 pm

SACRAMENTO, CA - At 4-years-old Rydr Rudgers is able to eat, speak, and walk --all thingshis family wasn't sure he'd ever do after being diagnosed with cerebral palsy as an infant.

"He was born without any brain stem functions; no sucking, no swallowing, no breathing," said Rydr's mother Elisa.

When Rydr was 15-months-old, he began stem cell infusions from his cord blood that was saved in a stem cell bank.Rydris making great progress after three infusionsand can even feed himself.

"These are like huge milestones that people don't think about, but actually being able to hold a fork and eat a sandwich is, in our world, an unanticipated milestone and it's amazing," Elisa Rudgers explained.

"Like autism, cerebral palsy or brain injuries of that nature are a diffused population, it's not one cause,"said Dr. Michael Chez, who is the Medical Director of Pediatric Neurology at the Sutter Neuroscience Institute.

Doctors at the Sutter Neuroscience Institute are now beginning research to evaluate cord blood stem cells to help improve language and behavior in autism patients.

The announcement was made on Tuesday morning at Sutter Medical Plaza.It's the first FDA-approved clinical trial that uses a newborn's stem cells from cord blood to treat autism patients.

Doctors will infuse umbilical cord stem cells into the bloodstreams of 30 children diagnosed with autism.

"We feel it will offer a safe and effective answer to the question of whether the cord blood is an effective intervention as a way to introduce stem cell therapy for autism," Chez said.

Autism impacts one in 88 children and one in 54 boys. According to Sutter doctors, a newborn's umbilical cord blood contains a unique population of stem cells that have been used for more than 20 years in medical practice.

Continue reading here:
Doctors to study newborn stem cells as treatment for autism

Posted in Stem Cells | Comments Off on Doctors to study newborn stem cells as treatment for autism

Stem Cells Fix Bladder Leakage in Mice, Study Finds

Posted: August 22, 2012 at 5:11 pm

TUESDAY, Aug. 21 (HealthDay News) -- Stem cells from amniotic fluid might one day help treat stress urinary incontinence, a condition caused by damaged pelvic floor muscles in which bladder leakage is brought on by exercise, coughing or simply laughing, a new study involving mice suggests.

Researchers in Korea found that this new technique repaired the damaged pelvic floor muscles in the mice, and kept the condition from recurring.

Results obtained in animal studies do not necessarily apply to humans, however, and much more research is needed before this might be considered a viable treatment for people.

Looking for an alternative to surgery to treat stress urinary incontinence, the scientists explored the use of stem cells to repair the weak muscles that cause bladder leakage. To do this in a noninvasive way, they used stem cells from amniotic fluid collected during routine amniocentesis (prenatal testing of amniotic fluid).

"These stem cells ... have the ability to become muscle cells when grown under the right conditions," explained the study's leaders, James Yoo and Tae Gyun Kwon, from Kyungpook National University, in a news release. "We found that the stem cells were able to survive for seven days inside the mice but by 14 days they had all disappeared. Nevertheless, they were able to induce regeneration of the mouse's own urethral sphincter muscle."

The study revealed the stem cells were able to strengthen the muscles of the pelvic floor. This regenerated muscle also had the right nerve connections. The researchers added that amniotic stem cells do not appear to cause an immune response, such as rejection or tumor growth. Exactly how the stem cells are able to regenerate the muscles remains unclear, they noted.

Stress urinary incontinence is common among women during and after pregnancy and in women aged 40 and older. The study authors noted that men also can develop the condition, particularly those who have undergone prostate surgery.

Current treatments for stress urinary incontinence include a combination of surgery, weight loss, pelvic floor exercises and bladder training.

The study was published Aug. 20 in the journal BMC Medicine.

-- Mary Elizabeth Dallas

Read the original here:
Stem Cells Fix Bladder Leakage in Mice, Study Finds

Posted in Stem Cells | Comments Off on Stem Cells Fix Bladder Leakage in Mice, Study Finds

Stem cells can become anything, but not without this protein

Posted: August 22, 2012 at 5:11 pm

ScienceDaily (Aug. 21, 2012) How do stem cells preserve their ability to become any type of cell in the body? And how do they "decide" to give up that magical state and start specializing?

If researchers could answer these questions, our ability to harness stem cells to treat disease could explode. Now, a University of Michigan Medical School team has published a key discovery that could help that goal become reality.

In the current issue of the journal Cell Stem Cell, researcher Yali Dou, Ph.D., and her team show the crucial role of a protein called Mof in preserving the 'stem-ness' of stem cells, and priming them to become specialized cells in mice.

Their results show that Mof plays a key role in the "epigenetics" of stem cells -- that is, helping stem cells read and use their DNA. One of the key questions in stem cell research is what keeps stem cells in a kind of eternal youth, and then allows them to start "growing up" to be a specific type of tissue.

Dou, an associate professor of pathology and biological chemistry, has studied Mof for several years, puzzling over the intricacies of its role in stem cell biology.

She and her team have zeroed in on the factors that add temporary tags to DNA when it's coiled around tiny spools called histones. In order to read their DNA, cells have to unwind it a bit from those spools, allowing the gene-reading mechanisms to get access to the genetic code and transcribe it. The temporary tags added by Mof act as tiny beacons, guiding the "reader" mechanism to the right place.

"Simply put, Mof regulates the core transcription mechanism -- without it you can't be a stem cell," says Dou. "There are many such proteins, called histone acetyltransferases, in cells -- but only MOF is important in undifferentiated cells."

Dou and her team also have published on another protein involved in DNA transcription, called WDR5, that places tags that are important during transcription. But Mof appears to control the process that actually allows cells to determine which genes it wants to read -- a crucial function for stem-ness. "Without Mof, embryonic stem cells lost their self-renewal capability and started to differentiate," she explains.

The new findings may have particular importance for work on induced pluripotent stem cells -- the kind of stem cells that don't come from an embryo, but are made from "adult" tissue.

IPCS research holds great promise for disease treatment because it could allow a patient to be treated with stem cells made from their own tissue. But the current way of making IPSCs from tissue involves a process that uses a cancer-causing gene -- a step that might give doctors and patients pause.

Link:
Stem cells can become anything, but not without this protein

Posted in Stem Cells | Comments Off on Stem cells can become anything, but not without this protein

Tissue engineering: The brainmaker

Posted: August 22, 2012 at 5:11 pm

HANS SAUTTER

In December 2010, Robin Ali became suddenly excited by the usually mundane task of reviewing a scientific paper. I was running around my room, waving the manuscript, he recalls. The paper described how a clump of embryonic stem cells had grown into a rounded goblet of retinal tissue. The structure, called an optic cup, forms the back of the eye in a growing embryo. But this one was in a dish, and videos accompanying the paper showed the structure slowly sprouting and blossoming. For Ali, an ophthalmologist at University College London who has devoted two decades to repairing vision, the implications were immediate. It was clear to me it was a landmark paper, he says. He has transformed the field.

'He' is Yoshiki Sasai, a stem-cell biologist at the RIKEN Center for Developmental Biology in Kobe, Japan. Sasai has impressed many researchers with his green-fingered talent for coaxing neural stem cells to grow into elaborate structures. As well as the optic cup1, he has cultivated the delicate tissue layers of the cerebral cortex2 and a rudimentary, hormone-making pituitary gland3. He is now well on the way to growing a cerebellum4 the brain structure that coordinates movement and balance. These papers make for the most addictive series of stem-cell papers in recent years, says Luc Leyns, a stem-cell scientist at the Free University of Brussels.

Sasai's work is more than tissue engineering: it tackles questions that have puzzled developmental biologists for decades. How do the proliferating stem cells of an embryo organize themselves seamlessly into the complex structures of the body and brain? And is tissue formation driven by a genetic program intrinsic to cells, or shaped by external cues from neighbouring tissues? By combining intuition with patient trial and error, Sasai has found that it takes a delicate balance of both: he concocts controlled environments that feed cells physical and chemical signals, but also gives them free rein to 'do their thing' and organize themselves into issues. He sometimes refers to himself as a Japanese matchmaker who knows that, having been brought together, two strangers need to be left alone. They know what to do, he says. They interact in a delicate manner, and if the external cues are too strong, it will override the internal ones.

Sasai's work could find medical applications. Recapitulating embryonic development in three dimensions, it turns out, generates clinically useful cells such as photoreceptors more abundantly and efficiently than two-dimensional culture can, and houses them in an architecture that mirrors that of the human body. Sasai and his collaborators are now racing to implant lab-grown retinas into mice, monkeys and humans. The way Sasai sees it, maturing stem cells in two-dimensional culture may lead to 'next generation' therapy but his methods will lead to 'next, next generation' therapy.

A bit stiff in movement and reserved in manner, Sasai nevertheless puts on a theatrical show with a cocktail shaker at parties held by his institute after international symposia. My second job is bartender, he says, without a trace of a smile. It is, however, the cocktails he mixes in 96-well culture plates that have earned him scientific acclaim.

Like many members of his family, Sasai studied medicine. But he soon became frustrated by the lack of basic understanding in the field, especially when it came to neurological conditions. Without knowing the brain, a doctor cannot do much for the patient and therapeutics will always be superficial, he recalls thinking. There seemed no better way to know the brain than to study how it emerges and folds in the embryo. It's complex and usually complex systems are messy, says Sasai. But it's one of the most ordered. He wanted to know how this elaborate system was controlled.

We set up the permissive conditions. But after that we don't do anything. Keep them growing and let them do their job.

One piece of the puzzle was well known: the Spemann organizer, a node in vertebrate embryos that induces surrounding cells to become neural tissue. How the organizer works had been a mystery since its discovery in 1924; to find out, Sasai accepted a postdoctoral position at the University of California, Los Angeles. The post got off to a difficult start when Sasai was robbed of his money and passports at the airport on his way to California. But his scientific efforts were soon rewarded. He replaced the passports and within a month produced the clones that gave us the famous gene chordin, says his supervisor, developmental biologist Eddy De Robertis.

Sasai and his colleagues discovered that the chordin protein is a key developmental signal released by the Spemann organizer5. Rather than pushing nearby cells to become neurons, they found, chordin blocks signals that would turn them into other cell types6, 7. The work helped to establish the default model of neural induction: the idea that, without other signals, embryonic cells will follow an internal program to become neural cells.

Read the rest here:
Tissue engineering: The brainmaker

Posted in Stem Cells | Comments Off on Tissue engineering: The brainmaker

New marker for identifying precursors to insulin-producing cells in pancreas

Posted: August 22, 2012 at 5:10 pm

Public release date: 21-Aug-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, August 21, 2012For the millions of people worldwide with type 1 diabetes who cannot produce sufficient insulin, the potential to transplant insulin-producing cells could offer hope for a long-term cure. The discovery of a marker to help identify and isolate stem cells that can develop into insulin-producing cells in the pancreas would be a critical step forward and is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article is available free online at the BioResearch Open Access website (http://www.liebertpub.com/biores).

Pancreatic stem cells, the precursors of insulin-producing cells, have not yet been identified in humans or animals, and there is much debate about where they may reside. Ivka Afrikanova, Ayse Kayali, Ana Lopez, and Alberto Hayek, University of California, San Diego, CA, have identified a biochemical markerstage-specific embryonic antigen 4 (SSEA4)that they propose can be used to identify and purify human pancreatic stem cells. The article "Is Stage-Specific Embryonic Antigen 4 a Marker for Human Ductal Stem/Progenitor Cells" (http://online.liebertpub.com/doi/full/10.1089/biores.2012.0235) reports that when grown in culture with high levels of glucose and B27, these SSEA4+ stem cells can differentiate into insulin-producing pancreatic cells.

###

About the Journal

BioResearch Open Access (http://www.liebertpub.com/biores) is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available online at the BioResearch Open Access website (http://www.liebertpub.com/biores).

About the Publisher

Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc. website (http://www.liebertpub.com).

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101

More:
New marker for identifying precursors to insulin-producing cells in pancreas

Posted in Genetic Engineering | Comments Off on New marker for identifying precursors to insulin-producing cells in pancreas

Stem Cells Could Reverse Incontinence

Posted: August 22, 2012 at 2:10 am

Researchers report that stem cells have reversed bladder leakage in mice, and that the discovery could pave the way for new treatments against urinary incontinence.

The study, conducted at Kyungpook National University in South Korea, found that weakened pelvic-floor muscles in mice were repaired with stem cells made from amniotic fluid. The stem cells also kept the condition from recurring, even though the cells disappeared after 14 days in the body.

Urinary incontinence will affect one out of every three women after age 40. Although men may also have the condition, the frequency is much lower. Treatments for urinary incontinence include surgery, lifestyle changes like weight loss, and exercises to strengthen pelvic muscles.

Previously, stem cell therapy has been suggested as a possibility for treating urinary incontinence, but the only way to gather the cells was through invasive procedures. Collecting stem cells from amniotic fluid is easier during a routine procedure of amniocentesis.

"These stem cells ... have the ability to become muscle cells when grown under the right conditions," study leaders James Yoo and Tae Gyun Kwon said in a statement.

Testing on people, though, is needed to back up the researchers findings.

The study was published in the journal BMC Medicine.

More:
Stem Cells Could Reverse Incontinence

Posted in Stem Cell Videos | Comments Off on Stem Cells Could Reverse Incontinence

Autism Stem-Cell Therapy to Be Tested in Kids in Trials

Posted: August 22, 2012 at 2:10 am

By Ryan Flinn - 2012-08-21T04:01:00Z

Researchers are recruiting autistic children for a study that will test whether injecting stem cells banked from their umbilical cords can lessen symptoms and provide insights into the nature of the disorder.

While stem cells have been promoted, and sold, as a treatment for autism, few clinical trials have been conducted to see whether theyre effective. The study, which begins enrolling patients today, is the first of its kind approved by the U.S. Food and Drug Administration to assess the use of stem cells as a potential autism therapy, said Michael Chez, director of pediatric neurology at Sutter Medical Center in Sacramento, California, and the principal investigator.

About 1 in 88 children in the U.S. are diagnosed with an autism-related condition. The disorder hurts brain development and is linked to poor social interaction and communication skills, repeated body movements, and unusual attachments to objects.

With this study well be able to answer in a firm way that this is truly an observed effect, or we didnt get an observed effect, Chez said in a phone interview.

Thirty children with autism, ages 2 to 7, will be divided in two groups, with one getting the stem cell injection and the other receiving a placebo shot. After six months, the groups will switch. Patients will be monitored for improvement in language as well as irritability and other autism rating scales.

Ricardo Dolmetsch, a neurobiologist at Stanford University in California whose laboratory is studying autism, said he doesnt think the trial will yield much in usable results, though hes glad the idea of using stem cells is being testing.

I commend them for having the guts to actually do it, given that there are all kinds of people out there trying to sell it, he said. On the other hand I dont think its big enough to provide an answer.

Chez theorizes that autism, which has no known cause or cure, may be spurred on by damaged nerve cells. Stem cells, the building blocks of life that can grow into any type of tissue in the body, could repair the damage or create new cells, he said. Such a mechanism would yield results in six to 12 months, the time it takes to create new cells.

Another possibility may be that autism is related to a signaling issue, where cells in the body arent connecting properly. Stem cells may help repair that problem, he said, and would be evident if results are seen within weeks of the injection. A third and more exploratory possibility is the disorder is related to inflammation, an immune system response.

Continued here:
Autism Stem-Cell Therapy to Be Tested in Kids in Trials

Posted in Stem Cell Videos | Comments Off on Autism Stem-Cell Therapy to Be Tested in Kids in Trials

Autism and Cord Blood Stem Cells: FDA Gives Green Light for Groundbreaking Clinical Trial

Posted: August 22, 2012 at 2:10 am

SACRAMENTO, Calif., Aug.21, 2012 /PRNewswire/ -- Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world's largest stem cell bank, are launching the first FDA-approved clinical trial to assess the use of a child's own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.

To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism

(Photo:http://photos.prnewswire.com/prnh/20120821/MM59477)

(Logo:http://photos.prnewswire.com/prnh/20120216/AQ54476LOGO)

According to the Centers for Disease Control and Prevention, autism spectrum disorders impact one in 88 children in the U.S., and one in 54 boys.1 The condition is thought to have multiple risk factors including genetic, environmental and immunological components.

"This is the start of a new age of research in stem cell therapies for chronic diseases such as autism, and a natural step to determine whether patients receive some benefit from an infusion of their own cord blood stem cells," said Michael Chez, M.D., director of Pediatric Neurology with the Sutter Neuroscience and principal study investigator. "I will focus on a select portion of children diagnosed with autism who have no obvious cause for the condition, such as known genetic syndromes or brain injury."

The study will enroll 30 children between the ages of two and seven, with a diagnosis of autism who meet the inclusion criteria for the study. Enrolled participants will receive two infusionsone of the child's own cord blood stem cells and one of a placeboover the course of 13 months. Both the participants and the lead investigators will be blinded from knowing the content of each infusion. To ensure the highest quality and consistency in cord blood stem cell processing, storage and release for infusion, CBR is the only family stem cell bank providing units from clients for the study.

For information on study, visit http://www.cordblood.com/autism.

Study Rationale

A newborn's umbilical cord blood contains a unique population of stem cells that have been used for more than 20 years in medical practice to treat certain cancers, blood diseases and immune disorders. When patients undergo a stem cell transplant for these conditions, the stem cells effectively rebuild the blood and immune systems.

See original here:
Autism and Cord Blood Stem Cells: FDA Gives Green Light for Groundbreaking Clinical Trial

Posted in Stem Cell Videos | Comments Off on Autism and Cord Blood Stem Cells: FDA Gives Green Light for Groundbreaking Clinical Trial

Stem Cells Can Become Anything – but Not Without This Protein

Posted: August 22, 2012 at 2:10 am

Newswise ANN ARBOR, Mich. -- How do stem cells preserve their ability to become any type of cell in the body? And how do they decide to give up that magical state and start specializing?

If researchers could answer these questions, our ability to harness stem cells to treat disease could explode. Now, a University of Michigan Medical School team has published a key discovery that could help that goal become reality.

In the current issue of the prestigious journal Cell Stem Cell, researcher Yali Dou, Ph.D., and her team show the crucial role of a protein called Mof in preserving the stem-ness of stem cells, and priming them to become specialized cells in mice.

Their results show that Mof plays a key role in the epigenetics of stem cells -- that is, helping stem cells read and use their DNA. One of the key questions in stem cell research is what keeps stem cells in a kind of eternal youth, and then allows them to start growing up to be a specific type of tissue.

Dou, an associate professor of pathology and biological chemistry, has studied Mof for several years, puzzling over the intricacies of its role in stem cell biology.

She and her team have zeroed in on the factors that add temporary tags to DNA when its coiled around tiny spools called histones. In order to read their DNA, cells have to unwind it a bit from those spools, allowing the gene-reading mechanisms to get access to the genetic code and transcribe it. The temporary tags added by Mof act as tiny beacons, guiding the reader mechanism to the right place.

Simply put, Mof regulates the core transcription mechanism without it you cant be a stem cell, says Dou. There are many such proteins, called histone acetyltransferases, in cells but only MOF is important in undifferentiated cells.

Dou and her team also have published on another protein involved in DNA transcription, called WDR5, that places tags that are important during transcription. But Mof appears to control the process that actually allows cells to determine which genes it wants to read a crucial function for stem-ness. Without Mof, embryonic stem cells lost their self-renewal capability and started to differentiate, she explains.

The new findings may have particular importance for work on induced pluripotent stem cells the kind of stem cells that dont come from an embryo, but are made from adult tissue.

IPCS research holds great promise for disease treatment because it could allow a patient to be treated with stem cells made from their own tissue. But the current way of making IPSCs from tissue involves a process that uses a cancer-causing gene a step that might give doctors and patients pause.

Read the original post:
Stem Cells Can Become Anything - but Not Without This Protein

Posted in Stem Cell Videos | Comments Off on Stem Cells Can Become Anything – but Not Without This Protein

Page 2,669«..1020..2,6682,6692,6702,671..2,6802,690..»